![](https://fbexternal-a.akamaihd.net/safe_image.php?d=AQD-QRSiqs97qj7m&w=470&h=246&url=http%3A%2F%2Fwww.rheumatologynews.com%2Fuploads%2Fpics%2Fmedia_3cad748_Hammitt_Katherine_Bethesda.jpg&cfs=1&upscale=1&sx=0&sy=17&sw=600&sh=314&ext=png2jpg)
SAN FRANCISCO – Rituximab is, for now, the first-line option for Sjögren’s syndrome patients with systemic symptoms severe enough to require biologic…
www.rheumatologynews.com|By M. ALEXANDER OTTO
Sjogren’s Syndrome US treatment guidelines: Rituximab is first line.
Towards personalised treatment in primary Sjögren’s syndrome: predicting response to Rituximab
![](https://fbexternal-a.akamaihd.net/safe_image.php?d=AQABW_wFXjX8lb3p&w=90&h=90&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fcoreutils%2Fimg%2Fpubmed256blue.png&cfs=1&upscale=1&ext=png2jpg)
ncbi.nlm.nih.gov|By Delli K , et al.
A high pretreatment number of CD20+ B cells/mm(2) parotid gland parenchyma predicts better responsiveness of patients with pSS to RTX treatment.